On 27th August 2025, Jeena Sikho Lifecare Limited (JSLL) announced a series of major developments following its Board of Directors meeting. The decisions, filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, cover significant areas such as Employee Stock Option Plans (ESOPs), leadership appointments, secretarial audits, annual reporting, and dividend distribution.

These approvals reflect the company’s ongoing commitment to governance, compliance, employee growth, and shareholder value creation. Below is a detailed breakdown of the nine major outcomes of the board meeting:

Approval of Employee Stock Option Scheme 2025 (ESOP 2025)

One of the most significant outcomes was the approval of the Employee Stock Option Scheme 2025. The scheme is designed to grant stock options to eligible directors, employees, and group companies including subsidiaries and associates.

• The scheme covers up to 2,50,000 stock options.

• Each option entitles an employee or director to acquire an equity share of the company.

• The exercise price is fixed at ₹2 per share, subject to shareholder and authority approval.

• The scheme is fully compliant with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

This initiative is expected to boost employee morale, align workforce incentives with company growth, and enhance long-term loyalty within the organisation.

Appointment of Mr. Sahil Jain as Chief Operating Officer (COO)

The board confirmed the appointment of Mr. Sahil Jain as the new Chief Operating Officer (COO) effective 27th August 2025.

• Sahil Jain has been with Jeena Sikho Lifecare for over 8 years.

• He previously led key departments such as IT, Marketing, Call Centre Operations, and Administration.

• His past corporate experience includes roles at IBM and HCL Australia.

• He holds a Bachelor of Commerce (B.Com) and a Master of Computer Applications (MCA).

As COO, he will be responsible for streamlining business functions, enhancing efficiency, and ensuring smooth operational execution across departments.

Appointment of M/s Ankur Singh & Associates as Secretarial Auditor

The company has appointed M/s Ankur Singh & Associates as the Secretarial Auditor for a term of five consecutive years (FY 2025-26 to FY 2029-30), subject to shareholder approval at the upcoming AGM.

• The firm holds a Peer Review Certificate No. 4377/2023.

• It specialises in corporate governance, RBI matters, legal advisory, due diligence, and compliance audits.

• The appointment aligns with Section 204 of the Companies Act, 2013 and Regulation 24A of SEBI Listing Regulations.

This move underscores the company’s commitment to strengthening corporate governance and compliance mechanisms.

Annual Report for FY 2024-25

The Annual Report for FY25 was also approved. It includes:

• Board’s Report

• Management Discussion & Analysis (MD&A)

• Business Responsibility & Sustainability Report (BRSR)

• CSR Report

This comprehensive reporting framework will provide shareholders with a detailed understanding of the company’s financial and non-financial performance.

Notice of 8th Annual General Meeting (AGM)

The board finalised the notice for the 8th AGM, scheduled to be held on:

• Date: 29th September 2025

• Time: 12:00 Noon

• Venue: First Floor, Parle G Godown, City Enclave, Back Side JP Hospital, Near Anand Complex, Zirakpur, SAS Nagar, Punjab

The AGM will cover all key shareholder approvals including ESOP 2025, appointments, dividend declaration, and approval of statutory reports.

Fixation of Dividend Record Date

The board reconfirmed its earlier recommendation of a final dividend of ₹1.10 per equity share (face value ₹2 each) for FY25.

• Record date: 22nd September 2025

• Payout: Post approval at AGM, dividend will be dispatched on or after 29th September 2025 within stipulated timelines.

This reinforces the company’s focus on rewarding shareholders while balancing growth investments.

Re-designation of Ms. Shreya Grover as Whole-time Director

The board approved the re-designation of Ms. Shreya Grover from Non-Executive Director to Whole-time Director & KMP effective 27th August 2025 for a five-year term.

• Shreya Grover, aged 24, has been associated with Jeena Sikho since June 2021.

• Daughter of Managing Director Mr. Manish Grover and Whole-time Director Mrs. Bhavna Grover.

• She has contributed significantly through marketing strategies, innovative sales ideas, and expansion into Ayurveda healthcare and OTC products.

• She will now actively drive the company’s future growth and governance in an executive role.

This move reflects the company’s next-generation leadership development strategy.

Appointment of Scrutinizer

The board appointed Mr. Vivek Rawal of M/s Rawal & Co., Practicing Company Secretary, as the Scrutinizer for remote e-voting at the 8th AGM. This ensures a fair and transparent voting process for all shareholders.

Book Closure

The board approved book closure from 23rd September 2025 to 29th September 2025 (both days inclusive) for AGM purposes.

Broader Significance of the Board Meeting

This Board Meeting outcome reflects Jeena Sikho Lifecare’s balanced approach to growth and governance.

• Employee empowerment through ESOPs ensures alignment of staff goals with shareholder value.

• Leadership changes strengthen operational execution and prepare the company for future expansion.

• Strong compliance mechanisms via secretarial audits highlight governance excellence.

• Shareholder rewards through dividends continue to build investor trust.

The meeting, which commenced at 2:00 PM IST and concluded at 4:30 PM IST, marks a critical milestone in Jeena Sikho Lifecare’s corporate journey, as the company prepares for its 8th AGM and beyond.

The Upcoming IPOs in this week and coming weeks are Amanta Healthcare, Rachit Paints, Abril Paper Tech, Sneha Organics, Sugs Lloyd, .

The Current active IPO are Anlon Healthcare, NIS Management, Sattva Engineering Construction, Globtier Infotech, Current Infraprojects, Vikran Engineering, Shivashrit Foods, Anondita Medicare, Classic Electrodes (India).

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.